Yunovia, the new drug research and development company of Ildong Pharmaceutical Group, presented research results related to its metabolic disease drug candidate 'ID110521156', which targets obesity and diabetes, at the American Diabetes Association (ADA) meeting held in Chicago, United States, from June 20 to June 23, 2025.
ID110521156 is a GLP-1 RA (glucagon-like peptide-1 receptor agonist) class drug that mimics the function of the GLP-1 hormone, which is involved in insulin synthesis and secretion, reduction of blood glucose levels, regulation of gastrointestinal motility, and appetite suppression in the body.
According to the company, ID110521156 is a synthetic oral (tablet) drug candidate based on a small molecule compound, which sets it apart from existing peptide-based injectable therapies by offering superior productivity and greater ease of use.
Yunovia is conducting clinical studies to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of ID110521156. The company completed a single ascending dose (SAD) Phase 1 clinical trial last year and is currently conducting a multiple ascending dose (MAD) follow-up study.
During the conference, Yunovia presented notable findings in a poster format, highlighting interim results and related data from both the single ascending dose and multiple ascending dose Phase 1 clinical trials of ID110521156.
According to the research poster, in the single ascending dose trial, ID110521156 demonstrated outstanding tolerability by showing significantly fewer gastrointestinal side effects across the effective dose range compared to existing GLP-1 RA class drugs.
For the ongoing multiple ascending dose trial, the study is being conducted by applying the effective dose directly?without a titration process to gradually increase the dose from a low starting point?based on the gastrointestinal tolerability confirmed in previous research.
Interim results from a clinical study in overweight healthy subjects showed that as the administered dose increased, blood drug concentrations also rose proportionally. This indicates that the drug is suitable for once-daily oral administration from both pharmacokinetic and pharmacodynamic perspectives. The study also confirmed efficacy in reducing blood glucose and body weight.
Among the different dosage cohorts, the group receiving 100 mg of the drug showed an average weight loss of 6.9% and a maximum of 11.9% over four weeks. The proportion of subjects who lost more than 5% of their body weight was 0% in the placebo group, but 55.6% in the 50 mg group and 66.7% in the 100 mg group, demonstrating clinically meaningful data.
No serious adverse reactions were observed in the safety and tolerability assessments, and there were no reports of trial discontinuation due to such events. In particular, side effects were only mild and there was no impact on liver toxicity indicators.
A representative from Ildong Pharmaceutical Group stated, "ID110521156 stands out as a non-peptide-based, orally administered small molecule synthetic drug in the GLP-1 RA class, which is rare. Through this study, we have also confirmed its excellent competitiveness in terms of tolerability and efficacy. We plan to accelerate commercialization efforts, including further clinical development and pursuing out-licensing (technology transfer) opportunities."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
